MedTrace Logo

Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.

NCT05189756 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2025-02-27

No results posted yet for this study

Summary

Postoperative nausea and vomiting (PONV) is unpleasant and increases health care costs. Despite modern techniques and prophylaxis, PONV rates remain high after laparoscopic bariatric surgery. We aim to reduce PONV after laparoscopic bariatric surgery using aprepitant with a similar scheme used for emetogenic chemotherapy.

Conditions

  • Postoperative Nausea and Vomiting
  • Bariatric Surgery

Interventions

DRUG

Aprepitant 80 mg

Encapsulated capsule of aprepitant 80mg to make it look alike to the placebo.

DRUG

Placebo

Encapsulated placebo capsules for optical, acoustical and haptic blinding.

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Christian M Beilstein, MD · Bern University Hospital, University of Bern, Bern, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-17
Primary Completion
2025-02-20
Completion
2025-02-20

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05189756 on ClinicalTrials.gov